Merck Completes Acquisition of Verona Pharma for $10 Billion, Adding Ohtuvayre to Cardio-Pulmonary Portfolio
ByAinvest
Tuesday, Oct 7, 2025 6:46 am ET1min read
MRK--
VRNA--
Merck has completed its acquisition of Verona Pharma, adding Ohtuvayre, a first-in-class maintenance treatment for chronic obstructive pulmonary disease (COPD), to its portfolio. The acquisition strengthens Merck's cardio-pulmonary pipeline and is expected to negatively impact non-GAAP EPS by $0.16 in the first 12 months. Ohtuvayre is a novel, inhaled mechanism for COPD maintenance treatment that combines bronchodilator and anti-inflammatory effects.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet